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A small group of HIV-1-infected individuals (5e15%) control
disease progression for several years in the absence of any
antiretroviral therapy. Among this group, elite controllers
(EC) spontaneously control HIV-1 replication (below 50 HIV-
1 RNA copies/ml).1
Homeostatic factors contribute to maintain a stable pool
of T cells in this situation where T cell apoptosis is
enhanced. This situation promotes the release of micro-
vesicles from cells, such as exosomes.2 One of the active
molecules carried by exosomes are miRNAs, small non-
coding RNA capable of recognizing specific mRNA and
inhibiting its translation into proteins. These molecules may
thus promote hematopoietic stem cells and regulate the
immune system and inflammatory processes that could in-
fluence the homeostasis cell equilibrium and a number of
immunomodulatory processes.2 HIV could interfere with
the exosomal pathway, enhancing or inhibiting the release
of exosomes or modifying their content, including host-
derived miRNA cargo.3
Previous studies have showed the relevance of miRNAs in
HIV pathogenesis. Whereas PBMCs-derived miR-150, miR-
29a and miR-31 have been reported to positively correlate
with CD4 counts, miR-181b has been associated negatively
comparing EC with viremic progressors.4 Other study
observed plasma miRNAs that correlated with CD4 count in
a group of EC and viremic progressors.5 We conducted this
cross-sectional study to analyze a set of exosome-derived
miRNAs that could predict the decay of CD4 levels among
an interesting group of patients who spontaneously control
HIV replication (elite controllers); EC with stable CD4 count
versus EC with significant decreased CD4 count. We also
investigated the association of plasma-derived exosome
miRNA levels with both soluble cytokine levels and cellular
immune activation.
Material and methods
This retrospective cross-sectional study included HIV-1-
infected elite controllers belonging to the multicentre
Spanish Elite Controllers (EC) Cohort of the Spanish AIDS
Research Network (ECRIS cohort), initiated in 2013.6 To be
included, patients had to be asymptomatic chronic HIV-1-
infected patients with at least three consecutive plasma
HIV-1 RNA loads below 50 HIV-RNA copies/mL during at
least 12 months in the absence of any antiretroviral ther-
apy. Elite controllers were classified in two groups; those
with stable or increasing CD4 T cell count during minimum
three years, named as stable CD4 T cell count elite con-
trollers (SEC, NZ 21); and those with significant decreased
CD4 T cell count, name as decreasing CD4 T cell count elite
controllers (DEC, N Z 11).Plasma and peripheral blood mononuclear cell samples,
provided by the Spanish HIV Biobank,7 were analyzed
before the classification into SEC and DEC groups. The first
plasma samples available after the inclusion of each pa-
tient in the cohort were used. Clinical and epidemiological
data were provided by the ECRIS Cohort. All procedures
were performed in accordance with the ethical standards
of the Institutional Review Boards of the participating
Hospitals, which complied with the stipulations of the
Declaration of Helsinki. Informed consent was obtained
from all individual participants included in the study.
EDTA-plasma was thawed and sequentially centrifuged
at 300 g for 10 min at room temperature, 2.000 g for 30 min
at 4 C, and finally at 10.000 g for 45 min at 4 C to remove
cells and cell debris. Thrombine and DNase treatments
were used to prevent platelet and DNA contamination,
respectively. Plasmas were then filtered through 0.2 mm
nylon syringe filter to eliminate larger vesicles such as large
extracellular vesicles and apoptotic bodies. Exosomes were
precipitated using miRCURY Exosome isolation kit (Exiqon
A/S, Vedbaek, Denmark). The ExoELISA-ULTRA CD63 assay
(SBI System Bioscience, Mountain View, CA, USA) was used
to quantitate exosome content into the samples.
RNA extraction from isolated exosome-enriched pellet
was performed using miRCURY RNA isolation kit-Biofluids
(Exiqon A/S). UniSp2-4-5 RNA templates were used as in-
ternal control. Eluted RNA was assayed for concentration
and purity (NanoDrop instrument, Thermo Scientific). All
RNA samples with 260/280 ratio between 1.8 and 2 and
260/230 ratio near 2 were considered suitable for further
analyses. Ten nanograms of RNA was reverse transcribed in
15 ml reactions (mirCURY LNA Universal RT microRNA PCR,
Exiqon A/S), including UniSp6 RNA spike-in template reac-
tion control. cDNA product was used for PCR reaction in
triplicate using ExiLENT SYBR Green Master Mix (Exiqon A/
S). LNA-based primers for hsa-miR-16-5p, hsa-miR-21-5p,
hsa-miR-29a-3p, hsa-miR-146a-5p, hsa-miR-221-3p and hsa-
miR-223-3p were used for individual qPCR assays using
LyghtCycler 480 II instrument (Roche, Basel, Switzerland).
Besides, miR-451a and miR-23a were tested to detect levels
of hemolysis.
Thermocycler conditions were as follows: 95 C hot start
for 10 min, followed by 40 cycles of 95 C for 15 s and 60 C
for 45 s. Amplification curves were analyzed using Roche
LightCycler 480 version 1.5.1.62 software. Reaction speci-
ficity was ascertained by performing the melt curve pro-
cedure. Ct values above 35 were considered negative and
excluded from the analysis. If the standard deviation be-
tween triplicates was above 0.3 Ct, the data point was
considered unreliable and excluded from further analysis.
MiR-103a-3p, miR-425-5p, and miR-93-5p were used as
reference for the calculation of DCt (Ct target miRNA -
mean references Ct) as normalization method.8 Expression
levels of the individual miRNAs relative to the mean
miR-21 in HIV-1 elite controllers 669reference expression of miRNAs were calculated as 2DCt.
Relative concentration of miRNAs was shown as log2 values.
Continuous variables were expressed as median and
interquartile range (IQ25e75), and categorical ones were
described by proportions. The ManneWhitney U test was
used to compare continuous variables and contingency ta-
bles for categorical variables. Uni and multivariate logistic
regression analysis was assessed using all independent
variables studied. Statistical analysis was performed using
SPSS software 16.0 (Chicago, Illinois, USA).Table 1 Characteristics of the patients at study point.
SEC pa
N 21
Age (years) 41.5 [
Gender (male) 6 (30%
Rout of transmission
Injecting drug user, n 14 (78
Heterosexual and MSM, n 4 (22%
Other, n 0 (0%)
Time maintaining EC status (months) 105 [8
CD4 T cell count at baseline (cells/mm3) 819 [6
CD4 T cell line at the end of follow up (cells/mm3) 856 [6
CD4 T cell slope (cells/mm3/year) 7.8 [
CD4 T cell count at study point (cells/mm3) 912 [8
HCV infection
Antibodies anti-HCV positive, n 15 (71
HCV PCR positive, n 11 (73
Natural HIV suppressive factorsa
MIP-1a (pg/mL) 8.31 [
MIP-1b (pg/mL) 112 [8
RANTES (pg/mL) 275 [2
Chemoattractant chemokinesa
Eotaxina (pg/mL) 19.2 [
GROa (pg/mL) 6.72 [
MCP-1 (pg/mL) 17.60
SDF1a (pg/mL) 212 [1
IL8 (pg/mL) 6.46 [
IP10 (pg/mL) 22.98
Inflammation interleukins and proteinsa
IL10 (pg/mL) 4.24 [
IL18 (pg/mL) 118 [5
IL6 (pg/mL) 23.40
TNFa (pg/mL) 17.30
sTNFRI (pg/mL) 450 [2
Apoptosis inducing proteinsa
TRAIL (pg/mL) 9.09 [
FasL (pg/mL) 5.05 [
Immune activationb
CD4þCD38þHLA-DRþ T cells (%) 0.34 [
CD8þCD38þHLA-DRþ T cells (%) 0.13 [
a The following ELISA kits (Affymetrix eBioscience, San Diego, CA,
(Austin, TX, USA): ProcartaPlex Human Chemokine 9plex panel Immu
MIP-1b, and RANTES; ProcartaPlex Simplex for IL-18, FasL, TRAIL, and
b Co-expression of CD38 and HLA-DR in CD4 and CD8 T cells (ant
cytometry was used as markers of cellular immune activation. Sample
(Sony Biothecnology) and a minimum of 105 CD3 T cells were acquire
ManneWhitney U test. SEC, stable CD4 T cell count elite controlle
controller; HCV, hepatitis C virus; MSM, men who have sex with men.
Significant when p < 0.05 in bold.Results
Characteristics of the patients at the moment of the study
are shown in Table 1. Median abundance of exosomes in SEC
group was of 3.2  109 [2.2  109 e 4.1  109] and in DEC
group was 2.8  109 [2.1  109 e 3.7  109], with no sta-
tistic difference (p Z 0.675). The level of normalization
miRNAs 103a-3p, 425-5p, and 93-5p were similar between
both groups of patients (p Z 0.920, p Z 0.923, and
p Z 0.875, respectively).tients DEC patients p value
11
34.0e47.7] 41.5 [38.2e48.2] 0.650
) 7 (70%) 0.056
%) 5 (50%) 0.010
) 3 (30%) 0.648
2 (20%) 0.073
3e122] 85 [81e131] 0.696
39e1113] 1053 [850e1153] 0.067
69e1161] 633 [503e978] 0.042
1.6e25.0] 46.7 [86.5 to 30.2] <0.001
00e1157] 669 [491e1404] 0.764
.4%) 7 (63.6%) 0.651
.3%) 4 (57.1%) 0.447
5.60e13.28] 10.67 [5.45e13.12] 0.933
1e119] 98 [86e114] 0.350
11e349] 293 [190e320] 0.735
17.78e29.97] 29.89 [23.49e54.93] 0.042
3.15e11.32] 6.19 [4.47e7.72] 0.611
[11.32e27.42] 17.60 [8.59e35.52] 0.767
89e284] 193 [169e237] 0.287
4.91e9.37] 5.19 [4.27e9.33] 0.582
[14.63e34.44] 30.52 [18.78e41.58] 0.268
4.08e4.36] 4.26 [4.08e4.43] 0.986
4e247] 258 [105e525] 0.200
[23.17e23.74] 23.50 [23.25e23.63] 0.983
[16.63e18.58] 17.67 [16.14e17.85] 0.800
77e1263] 1500 [555e2060] 0.018
5.39e14.19] 4.39 [2.26e13.37] 0.287
3.97e6.60] 4.33 [3.49e5.41] 0.171
0.24e0.42] 0.28 [0.19e0.52] 0.667
0.09e0.25] 0.13 [0.08e0.26] 0.832
California, USA) were performed using Luminex 100 analyzer
noassay for Eotaxin, GRO-a, IL-8, IP-10, MCP-1, SDF-1a, MIP-1a,
sTNF-RI; ProcartaPlex High Sensitivity for IL-6, IL-10, and TNF-a.
ibodies from Sony Biotechnology, Surrey, UK) measured by flow
acquisition was performed on an SP6800 Spectral flow cytometer
d for further analysis.
r; DEC, decreasing CD4 T cell count elite controllers; EC, elite
670 M.J. Ruiz-de-Leo´n et al.As shown in Fig. 1, significant lower expression of miR-16
and miR-21 was found in DEC patients compared to SEC pa-
tients (p Z 0.034 and p < 0.001, for miR-16 and miR-21,
respectively), while significant higher levels of miR-221 was
found in DEC patients (pZ 0.025). The level of miR-29a, miR-
146 and miR-223 were similar between DEC and SEC patients.
Multivariable logistic regression model performed with
dependent categorical variable group (DEC versus SEC) and
significant miRs in univariate logistic regression model (miR-
16, miR-21 and miR-221) as independent variables, showed
that only miR-21 was independently associated to CD4 T cell
decline (OR 0.369, 95% CI 0.137e0.994, p Z 0.049). Signifi-
cant negative correlation between miR-21 and MCP-1 was
found among the EC patients (r Z 0.532, p Z 0.042), but
was evident only among DEC patients (r Z 0.649,
p Z 0.020). No other correlations between miR-21 and nat-
ural HIV suppressive factors, inflammation interleukins/pro-
teins, apoptosis or T cell activation were found.
Discussion
Plasma exosome-derived miR-16 and miR-21 were down-
regulated in DEC patients in comparison with SEC patients
with stable CD4 T cell count along time. On the other hand,Figure 1. Relative expression of extracellular vesicle-derived miR
patients) and decreasing CD4 T cell count (DEC patients) during thmiR-221 was upregulated in DEC patients compared to SEC
patients. Multivariate logistic regression model performed
to analyze whether miR-16, miR-21 and miR-221 were
independently associated to CD4 evolution in EC patients
(SEC versus DEC patients), showed that only miR-21 was
independently associated. While TNFR1 and eotaxin levels
were significantly higher in DEC patients, unfortunately,
none of the miRs analyzed correlated with the levels of
these soluble markers.
Despite there are many published works investigating
the role of miRNAs in the HIV-1 pathogenesis and disease
progression, only a few works have focused on the differ-
entially miRNA profile in HIV elite controllers (EC). Two of
them showed that some PBMC-derived miRNAs are differ-
entially expressed in EC. One showed that miR-146a and
miR-16 were not differentially expressed in EC compared to
viremic progressors or patients under ART, although miR-
221 was significantly upregulated in EC.9 The other work
found that miR-29a was upregulated in EC in comparison
with viremic progressors.4 Only one work reported that
plasma miR-146a was upregulated in EC in comparison with
chronic HIV infected patients.5
MiR-21 has been reported to provide a link between
inflammation and cancer. It is strongly involved in apoptosisNAs of HIV-1 elite controllers with stable CD4 T cell count (SEC
e follow up. ManneWhitney U test. Significant when p < 0.05.
miR-21 in HIV-1 elite controllers 671and cell proliferation and several targets have been validated
with experimental data.10 Targets includeB-cell translocation
gene 2, a tumor suppressor gene,11 the PI3K/Akt signaling
pathway, inhibiting apoptosis,12 or SMAD7, TGF-b negative
regulator, inhibiting cell proliferation,13 among others.
DEC patients showed negative CD4 T cell slope which is
consistent with a decrease of cell proliferation, but these
patients did not show different levels in apoptosis-related
proteins such as FasL or TRAIL. Moreover, no association
between miR-21 with immune activation markers was found.
Only the monocyte chemoattractant protein 1 (MCP-1)
was negatively associated to the expression of miR-21. This
could increase local inflammation leading to a decrease of
cell proliferation. Interestingly, this negative correlation
was only evident among DEC patients, suggesting that the
decrease in the level of miR-21 could start increasing the
levels of MCP-1 which could be a predictive value for the
future decrease of CD4 count. Unfortunately, at the time of
this study the levels of MCP-1 were similar between SEC and
DEC patients. It is not described whether MCP-1 gene could
be the target for miR-21.
One limitation of this study was the low number of pa-
tients analyzed, despite the intrinsic difficulty of sample
availability of this kind of patients. Another limitation is
that no other time point was available to perform a pro-
spective analysis.
Overall, exosome-derived miR-21 might be used as a
valuable predictive soluble biomarker to define HIV-1 elite
controllers who will show significant decay in their CD4 T
cell counts throughout time. Before the translation of the
role of miR-21 to the clinical practice it is necessary to
relate the expression of this miR with a specific molecular
change within the cell.Conflicts of interest
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We want to thank all the patients for their participation. This
study would not have been possible without the collaboration
of medical, nursery staff and data managers who have taken
part in the project. The members of the ECRIS Network are:IIS-Fundacio´n Jimenez Dı´az, UAM, Madrid: JM Benito, N Ral-
lo´n, C Restrepo, N Rodrı´guez, M Garcı´a, A Cabello, M Gor-
golas. Instituto Salud Carlos III, Madrid: S Resino, V Briz, MA
Jime´nez, MS Va´zquez, A Ferna´ndez, P Garcı´a. Hospital Gre-
gorio Maran˜o´n, Madrid: MA Mun˜oz, J Sa´nchez, JL Jime´nez, D
Sepu´lveda, I Garcı´a, I Consuegra. Hospital Clinic, Barcelona:
A Leo´n, M Arnedo, M Plana, N Climent, F Garcı´a. Hospital
Virgen del Rocio, Sevilla: E Ruiz-Mateos, B Domı´nguez, L
Taranco´n, M Rafii-El-Idrissi, MJ Polaino, M Genebat, P Vici-
ana, M Leal. Hospital Joan XXIII, Tarragona: F Vidal, E
Rodrı´guez, C Vilade´s, J Peraire. Centro Sandoval, Madrid: J
Romero, C Rodrı´guez, M Vera. Fundacion IRSI CAIXA, Bada-
lona: J Este´, E Ballana, MA Martı´nez, S Franco, M Nevot.
Hospital Ramo´n y Cajal, Madrid: A Vallejo, S Moreno. Instituto
Salud Carlos III, Madrid: M Pernas, C Casado, C Lo´pez. Insti-
tuto Salud Carlos III, Madrid: L Capa, M Pe´rez, J Alcami.
Universidad de Valencia: R Sanjua´n, JM Cuevas. Hospital 12
de Octubre, Madrid: R Delgado, O Sierra. Universidad de la
Laguna, Sta. Cruz Tenerife: A Valenzuela. The clinical centers
that contributed to ECRIS are listed in Supplementary file.References
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